Clinical Trial Update: Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a fixed combination intravitreal injection targeting anti-angiopoietin 2 and anti-VEGF for neovascular age-related macular deg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor (not specified)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2019-05-07